Information  X 
Enter a valid email address

Genesis Emerging (GSS)

  Print   

Friday 21 June, 2019

Genesis Emerging

Directorate Change

RNS Number : 0715D
Genesis Emerging Markets Fund Ld
21 June 2019
 

Genesis Emerging Markets Fund Limited ('the Fund')

Legal Entity Identifier: 213800HWWQPUJ4K1GS84

 

 

Board changes

 

In accordance with Listing Rule 9.6.13, the Board announces that Dr John Llewellyn has retired from his position as a non-executive director of the Fund with immediate effect.

 

Helene Ploix, Chairman of Genesis Emerging Markets Fund said "Dr Llewellyn has been an extremely valuable member of the Board over the past nine years. His presence will be much missed by his fellow Directors and we extend our thanks to him for his valuable contribution during his term in office".

 

Also in accordance with Listing Rule 9.6.13, the Board is pleased to announce the appointment of Dr Simon Colson as an independent non-executive director of the Fund with effect from 1st July 2019 and will be subject to formal shareholder approval at the Fund's forthcoming Annual General Meeting on 4th November 2019.

 

Simon has over 30 years' experience in financial markets, working in investment banking, investment management and financial consulting. From 1995-2001 he was Managing Director, Deutsche Bank AG London, in charge of Closed-end Fund Origination and Distribution, and in previous roles was responsible for the launch, restructuring and repurposing of a significant number of investment companies. From 2002-2005 he was a non-executive director of The Association of Investment Companies. In 2002 Simon started his own FCA regulated consulting and distribution business which raised assets for emerging managers across a range of traditional and alternative asset classes (including closed-end funds) over 15 years. In 2017 he relinquished his FCA licence to concentrate on unregulated advisory and non-executive work. Simon is currently a non-executive director of the Children's Liver Disease Foundation. He is a qualified medical doctor and holds an MBA in Finance & Investment from Cass Business School (University of London).

 

There are no other details to be disclosed under paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.

 

 

For further information, please contact:

 

J.P. Morgan Administration Services (Guernsey) Limited

Company Secretary

01481 758 620

 

21st June 2019

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOALLFEFRFILFIA

a d v e r t i s e m e n t